Table 3 BCMA-targeted CAR-T clinical trials
Trial ID | Conductor (reagent) | No. of evaluable patients | No. of median prior lines | Outcome | PFS | CRS | References |
|---|---|---|---|---|---|---|---|
NCT02215967 | National Cancer Institute | 26 | 9.5 | sCR: 2; CR: 1; VGPR:7; PR: 5; SD: 10; PD: 1; ORR 81% | EFS 31Â weeks | 2 G1, 7 G2, 3 G3, 1 G4 | [94] |
NCT02658929 | Bluebird bb2121 | 33 | 7 | sCR: 12; CR: 3; VGPR: 9; PR: 4; SD: 4; PD: 1; ORR 85% | 11.8 months | 23 G1–2, 2 G3 | [96] |
NCT03274219 | Bluebird bb21217 | 22 | 7 | ORR 83%; MRD negative: 10 at month 1 | NA | 5 G1, 7 G2, 1 G3 | [97] |
NCT03090659 | Nanjing Legend LCAR-B38M | 55 | 3 | CR: 39; VGPR: 3; PR: 8; SD: 4; PD: 1; ORR 88% | 20 months | 46 G1–2, 4 G3 | [98] |
NCT03090659 | Nanjing Legend LCAR-B38M | 17 | 4 | sCR: 13; VGPR: 2; SD:1; PD: 1; ORR 88.2% | 12 months | 10 G1–2, 6 G3, 1 G5 | [100] |
NCT03548207 | Legend Biotech JNJ-68284528 | 29 | 5 | sCR: 86%; PR: 3%; ORR 100% | 26/29 (90%) PFS at median 9-mon follow-up | 25 G 1–2, 1 G 3, 1 G5 | [102] |
NCT03430011 | Bristol JCARH125 | 62 | 6 | sCR + CR: 17; VGPR: 11; PR: 12; ORR 91% | NA | 53 G1–2, 2 G3–4 | [103] |
NCT03915184 | CARsgen Therapeutics CT053 | 13 | 4 | CR: 2; VGPR: 6; PR: 4; ORR 100% | NA | 1 G1, 1 G2, 1 G3 | [104] |
NA | Poseida Therapeutics MCARH171 | 11 | 6 | ORR 64%; median DOR: 106 days | NA | 4 G1–2, 2 G3 | [105] |
ChiCTR1800018137 | Nanjing Iaso Biotherapeutics CT103A | 9 | 4 | CR: 4; PR: 3; MR: 1; SD: 1; ORR 100% | NA | Cases were G0–2 | [106] |